Drug survival of biologic treatments in psoriasis: a systematic review
Drug survival measures the length of time until discontinuation of a drug. The length of time a patient remains on a biologic drug is impacted by several factors such as tolerability, side effects, safety profile and effectiveness. To evaluate the long-term drug survival, data of the most commonly p...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-07-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2017.1398393 |
| _version_ | 1797683725937410048 |
|---|---|
| author | Daniel J. No Megan S. Inkeles Mina Amin Jashin J. Wu |
| author_facet | Daniel J. No Megan S. Inkeles Mina Amin Jashin J. Wu |
| author_sort | Daniel J. No |
| collection | DOAJ |
| description | Drug survival measures the length of time until discontinuation of a drug. The length of time a patient remains on a biologic drug is impacted by several factors such as tolerability, side effects, safety profile and effectiveness. To evaluate the long-term drug survival, data of the most commonly prescribed biologic medications used in the treatment of psoriasis, a systematic review was conducted. A literature search using PubMed, the Cochrane Library and the Cumulative Index to Nursing and Allied Health Literature from January 1 2010 to October 28 2016 identified 3734 abstracts. Of which, 36 publications with over 40,000 patients met the inclusion criteria. The median overall drug survival for ustekinumab, adalimumab, infliximab and etanercept was 38.0, 36.5, 26.6 and 24.7 months, respectively. The mean annual drug survival rate of TNF inhibitors was 70%, 57%, 51%, 45% and 41% at years-1, 2, 3, 4 and 5, respectively. The 5-year mean annual drug survival rate of ustekinumab was 87%, 78%, 70%, 71% and 51%, respectively. Based on our findings, ustekinumab appears to have a longer drug survival with lower rates of discontinuation compared to tumor necrosis factor inhibitors. |
| first_indexed | 2024-03-12T00:18:56Z |
| format | Article |
| id | doaj.art-27a5ad0b1a294838bddfe65b25ec3ad1 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:18:56Z |
| publishDate | 2018-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-27a5ad0b1a294838bddfe65b25ec3ad12023-09-15T14:08:31ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532018-07-0129546046610.1080/09546634.2017.13983931398393Drug survival of biologic treatments in psoriasis: a systematic reviewDaniel J. No0Megan S. Inkeles1Mina Amin2Jashin J. Wu3Loma Linda University School of MedicineKaiser Permanente Los Angeles Medical CenterUniversity of California Riverside School of MedicineKaiser Permanente Los Angeles Medical CenterDrug survival measures the length of time until discontinuation of a drug. The length of time a patient remains on a biologic drug is impacted by several factors such as tolerability, side effects, safety profile and effectiveness. To evaluate the long-term drug survival, data of the most commonly prescribed biologic medications used in the treatment of psoriasis, a systematic review was conducted. A literature search using PubMed, the Cochrane Library and the Cumulative Index to Nursing and Allied Health Literature from January 1 2010 to October 28 2016 identified 3734 abstracts. Of which, 36 publications with over 40,000 patients met the inclusion criteria. The median overall drug survival for ustekinumab, adalimumab, infliximab and etanercept was 38.0, 36.5, 26.6 and 24.7 months, respectively. The mean annual drug survival rate of TNF inhibitors was 70%, 57%, 51%, 45% and 41% at years-1, 2, 3, 4 and 5, respectively. The 5-year mean annual drug survival rate of ustekinumab was 87%, 78%, 70%, 71% and 51%, respectively. Based on our findings, ustekinumab appears to have a longer drug survival with lower rates of discontinuation compared to tumor necrosis factor inhibitors.http://dx.doi.org/10.1080/09546634.2017.1398393psoriasisdrug survivalbiologicdiscontinuetumor necrosis factor inhibitorustekinumab |
| spellingShingle | Daniel J. No Megan S. Inkeles Mina Amin Jashin J. Wu Drug survival of biologic treatments in psoriasis: a systematic review Journal of Dermatological Treatment psoriasis drug survival biologic discontinue tumor necrosis factor inhibitor ustekinumab |
| title | Drug survival of biologic treatments in psoriasis: a systematic review |
| title_full | Drug survival of biologic treatments in psoriasis: a systematic review |
| title_fullStr | Drug survival of biologic treatments in psoriasis: a systematic review |
| title_full_unstemmed | Drug survival of biologic treatments in psoriasis: a systematic review |
| title_short | Drug survival of biologic treatments in psoriasis: a systematic review |
| title_sort | drug survival of biologic treatments in psoriasis a systematic review |
| topic | psoriasis drug survival biologic discontinue tumor necrosis factor inhibitor ustekinumab |
| url | http://dx.doi.org/10.1080/09546634.2017.1398393 |
| work_keys_str_mv | AT danieljno drugsurvivalofbiologictreatmentsinpsoriasisasystematicreview AT megansinkeles drugsurvivalofbiologictreatmentsinpsoriasisasystematicreview AT minaamin drugsurvivalofbiologictreatmentsinpsoriasisasystematicreview AT jashinjwu drugsurvivalofbiologictreatmentsinpsoriasisasystematicreview |